Susan P. Perrine, MD
President and Chief Scientific Officer
Dr. Susan Perrine specializes in translating bench discoveries into clinical therapeutics for neglected and serious diseases. She has developed first-in-man therapies and improved generations of therapeutics, liaising with medicinal and physical chemistry, formulation, toxicology, and regulatory experts. As Chief Scientific Officer, VP Clinical Affairs of HemaQuest Pharmaceuticals, she directed international clinical trials, working with specialty clinical researchers in 7 countries. Dr. Perrine is also Professor of Medicine, Pediatrics, Pharmacology and Experimental Therapeutics at Boston University Cancer Research Center. Her medical and specialty training were from Tufts University School of Medicine and Tufts Medical Center, Harvard School of Public Health, Children’s Hospital Boston, Dana-Farber Cancer Institute, and Harvard Medical School.
Thomas Dahl, PhD.
Chief Executive Officer
Dr. Dahl is a veteran of biotechnology from start-up to large pharma, with cross-team experience in drug development, clinical trials, and business management. He has served as VP Development, COO, and CEO of multiple successful companies. Dr. Dahl joined Phoenicia in 2014 and leads business development and partnering operations. A former faculty member at Tufts University, he received his PhD in Genetics and Biochemistry from the Johns Hopkins University.
Douglas V. Faller, MD, PhD
Chief Scientific Officer; Chairman, Scientific Advisory Board
Douglas V. Faller, MD, PhD, inventor of the virology and oncology technology platforms, has expertise across a broad range of molecular and cellular oncology, signaling, genetics, and clinical programs. He has developed novel approaches to disrupting the uncontrolled growth of multiple cancer types. As Karin Grunebaum Professor for Cancer Research, Director of the Boston University Cancer Center, Vice-Chairman of the Department of Medicine, he directs basic science and oversees clinical trials. Dr. Faller received his MD, PhD and subspeciality training at Harvard Medical School, MIT, the University of California San Francisco, Brigham and Women’s Hospital, Dana-Farber Cancer Institute, Boston Children’s Hospital, Harvard Medical School. Dr. Faller is a Scientific Co-founder of HemaQuest Pharmaceuticals.
John D. Schindler, Ph.D.
Vice-President, Clinical and Regulatory Affairs
John D. Schindler, Ph.D. is a veteran global pharmaceutical development executive, has filed 25 INDs, developed global regulatory strategy, directed clinical trials and registered novel therapeutics in past positions including World Wide Medical Director at Biogen, Ortho Pharmaceuticals, and VP, Dallas Biomedical. Achievements include registration of the first monoclonal antibody OKT3, gamma interferon in Germany, and Erythropoietin in Europe. He has liaised between large pharma, CROs, CMOs, clinical researchers in the US and Europe. Dr. Schindler received his B.S. from Brown University, and his Ph.D. from the Massachusetts Institute of Technology.
James Remenick, PhD, JD
Intellectual Property Counsel
James Remenick, Ph.D., J.D. works strategically with Phoenicia to develop and maximize the company’s valuable intellectual property rights, matching promising technology with concrete protection. Dr. Remenick and the Firm of Remenick PLLC work with Phoenicia in all aspects of intellectual property protection and enforcement including litigation, prosecution, licensing, opinions, consulting, and counseling. Dr. Remenick is admitted to the Bars of Washington, DC, Maryland and Texas, and is licensed to practice before the U.S. Patent and Trademark Office, multiple circuit and regional courts and the US Supreme Court. Dr. Remenick received his J.D. from the American University, Washington College of Law, his Ph.D. from the Department of Microbiology of the Uniformed Services University of the Health Sciences, and was a researcher at the Laboratory of Molecular Virology of the National Cancer Institute at the National Institutes of Health.
Jason Walsh, MBA was Co-Founder, Provenance Biopharmaceuticals, a cancer therapeutic company where he was Chief Business Officer and oversaw all corporate finance and business functions. Previously, Mr. Walsh led all business activities for the biotechnology company, Lexigen Pharmaceuticals Corp. He raised significant capital and partnership funding and managed competitive due diligence initiatives, which culminated in the Company’s acquisition by the European pharmaceutical company, Merck KGaA. Additionally, his efforts were instrumental in orchestrating the transaction and in the Company’s transition from an independent entity to a wholly-owned subsidiary of this global pharmaceutical concern. Mr. Walsh led the business functions for this Merck KGaA business unit until he and Dr. Gillies started Provenance Biopharmaceuticals Corp. and licensed the DI-Leu16-IL2 from Merck KGaA.